{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T11:50:48Z","timestamp":1792151448118,"version":"4.4.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["NSFC 82273549"],"award-info":[{"award-number":["NSFC 82273549"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"DOI":"10.1007\/s40259-026-00809-6","type":"journal-article","created":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T11:08:41Z","timestamp":1792148921000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Incidence and Risk Factors of Treatment-Emergent Eczematous Reactions in Patients with Psoriasis Treated with Biologics: A Systematic Review and Meta-Analysis"],"prefix":"10.1007","author":[{"given":"Yifei","family":"Feng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7159-879X","authenticated-orcid":false,"given":"Yan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,16]]},"reference":[{"issue":"19","key":"809_CR1","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1001\/jama.2020.4006","volume":"323","author":"AW Armstrong","year":"2020","unstructured":"Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323(19):1945\u201360.","journal-title":"JAMA"},{"issue":"1","key":"809_CR2","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s40259-022-00569-z","volume":"37","author":"Y Jiang","year":"2023","unstructured":"Jiang Y, Chen Y, Yu Q, Shi Y. Biologic and small-molecule therapies for moderate-to-severe psoriasis: focus on psoriasis comorbidities. BioDrugs. 2023;37(1):35\u201355.","journal-title":"BioDrugs"},{"issue":"6","key":"809_CR3","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1111\/ced.15130","volume":"47","author":"A Al-Janabi","year":"2022","unstructured":"Al-Janabi A, Foulkes AC, Griffiths CEM, Warren RB. Paradoxical eczema in patients with psoriasis receiving biologics: a case series. Clin Exp Dermatol. 2022;47(6):1174\u20138.","journal-title":"Clin Exp Dermatol"},{"issue":"1","key":"809_CR4","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1001\/jamadermatol.2023.4846","volume":"160","author":"A Al-Janabi","year":"2024","unstructured":"Al-Janabi A, Alabas OA, Yiu ZZN, Foulkes AC, Eyre S, Khan AR, et al. Risk of paradoxical eczema in patients receiving biologics for psoriasis. JAMA Dermatol. 2024;160(1):71\u20139.","journal-title":"JAMA Dermatol"},{"key":"809_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.847160","volume":"13","author":"W Xie","year":"2022","unstructured":"Xie W, Xiao S, Huang H, Zhang Z. Incidence of and risk factors for paradoxical psoriasis or psoriasiform lesions in inflammatory bowel disease patients receiving anti-TNF therapy: systematic review with meta-analysis. Front Immunol. 2022;13:847160.","journal-title":"Front Immunol"},{"issue":"5","key":"809_CR6","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1111\/ced.15052","volume":"47","author":"M Megna","year":"2022","unstructured":"Megna M, Caiazzo G, Parisi M, Ruggiero A, Capasso G, Mascolo M, et al. Eczematous drug eruption in patients with psoriasis under anti-interleukin-17A: does interleukin-22 play a key role? Clin Exp Dermatol. 2022;47(5):918\u201325.","journal-title":"Clin Exp Dermatol"},{"issue":"12","key":"809_CR7","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1111\/jdv.19394","volume":"37","author":"X Tang","year":"2023","unstructured":"Tang X, Li Q, Zhou Y, Zheng X, Zhou C, Hu Y, et al. Predictive factors of atopic-like dermatitis induced by IL-17A inhibitors in patients with psoriasis: a 2-year follow-up study. J Eur Acad Dermatol Venereol. 2023;37(12):2509\u201316.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"809_CR8","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1111\/jdv.17002","volume":"35","author":"C Bodemer","year":"2021","unstructured":"Bodemer C, Kaszuba A, Kingo K, Tsianakas A, Morita A, Rivas E, et al. Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52-week results from a phase 3 double-blind randomized, controlled trial. J Eur Acad Dermatol Venereol. 2021;35(4):938\u201347.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"809_CR9","doi-asserted-by":"publisher","DOI":"10.1111\/exd.14890","volume":"33","author":"J Zhou","year":"2024","unstructured":"Zhou J, Yuan Y, Liu Y, Chu M, Liu H, Liu Q, et al. Effectiveness and safety of secukinumab in Chinese patients with moderate to severe plaque psoriasis in real-world practice. Exp Dermatol. 2024;33(1):e14890.","journal-title":"Exp Dermatol"},{"issue":"11","key":"809_CR10","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1093\/ced\/llaf271","volume":"50","author":"G Caldarola","year":"2025","unstructured":"Caldarola G, De Luca E, Amato S, Belcastro A, Bernardini N, Bianchi L, et al. Predictive factors for eczematous eruptions and candidiasis during anti-interleukin-17 treatment in patients with psoriasis: a multicentre real-life experience in Lazio region, Italy. Clin Exp Dermatol. 2025;50(11):2185\u201391.","journal-title":"Clin Exp Dermatol"},{"issue":"3","key":"809_CR11","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.jdermsci.2011.05.005","volume":"63","author":"T-F Tsai","year":"2011","unstructured":"Tsai T-F, Ho J-C, Song M, Szapary P, Guzzo C, Shen Y-K, et al. Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL). J Dermatol Sci. 2011;63(3):154\u201363.","journal-title":"J Dermatol Sci"},{"issue":"12","key":"809_CR12","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1111\/1346-8138.12668","volume":"41","author":"M Ohtsuki","year":"2014","unstructured":"Ohtsuki M, Morita A, Abe M, Takahashi H, Seko N, Karpov A, et al. Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 study. J Dermatol. 2014;41(12):1039\u201346.","journal-title":"J Dermatol"},{"issue":"1","key":"809_CR13","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jaad.2024.09.031","volume":"92","author":"K Yan","year":"2025","unstructured":"Yan K, Li F, Bi X, Han L, Zhang Z, Chen R, et al. Efficacy and safety of vunakizumab in moderate-to-severe chronic plaque psoriasis: a randomized, double-blind, placebo-controlled phase 3 trial. J Am Acad Dermatol. 2025;92(1):92\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"809_CR14","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jdermsci.2010.04.014","volume":"59","author":"H Torii","year":"2010","unstructured":"Torii H, Nakagawa H, Japanese Infliximab Study i. Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial. J Dermatol Sci. 2010;59(1):40\u20139.","journal-title":"J Dermatol Sci"},{"issue":"5","key":"809_CR15","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1111\/1346-8138.16740","volume":"50","author":"S Imafuku","year":"2023","unstructured":"Imafuku S, Tada Y, Hippeli L, Banerjee S, Morita A, Ohtsuki M. Efficacy and safety of the selective TYK2 inhibitor, deucravacitinib, in Japanese patients with moderate to severe plaque psoriasis: subgroup analysis of a randomized, double-blind, placebo-controlled, global phase 3 trial. J Dermatol. 2023;50(5):588\u201395.","journal-title":"J Dermatol"},{"issue":"6","key":"809_CR16","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1111\/bjd.21743","volume":"187","author":"A Blauvelt","year":"2022","unstructured":"Blauvelt A, Kimball AB, Augustin M, Okubo Y, Witte MM, Capriles CR, et al. Efficacy and safety of mirikizumab in psoriasis: results from a 52-week, double-blind, placebo-controlled, randomized withdrawal, phase III trial (OASIS-1). Br J Dermatol. 2022;187(6):866\u201377.","journal-title":"Br J Dermatol"},{"issue":"4","key":"809_CR17","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1007\/s13555-021-00554-4","volume":"11","author":"L Puig","year":"2021","unstructured":"Puig L, Bakulev AL, Kokhan MM, Samtsov AV, Khairutdinov VR, Morozova MA, et al. Efficacy and safety of Netakimab, a novel anti-IL-17 monoclonal antibody, in patients with moderate to severe plaque psoriasis. Results of a 54-week randomized double-blind placebo-controlled PLANETA clinical trial. Dermatol Ther (Heidelb). 2021;11(4):1319\u201332.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"3","key":"809_CR18","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1111\/bjd.16236","volume":"178","author":"O Nemoto","year":"2018","unstructured":"Nemoto O, Hirose K, Shibata S, Li K, Kubo H. Safety and efficacy of guselkumab in Japanese patients with moderate-to-severe plaque psoriasis: a randomized, placebo-controlled, ascending-dose study. Br J Dermatol. 2018;178(3):689\u201396.","journal-title":"Br J Dermatol"},{"issue":"5","key":"809_CR19","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/j.jaad.2019.01.066","volume":"80","author":"U Mrowietz","year":"2019","unstructured":"Mrowietz U, Bachelez H, Burden AD, Rissler M, Sieder C, Orsenigo R, et al. Secukinumab for moderate-to-severe palmoplantar pustular psoriasis: results of the 2PRECISE study. J Am Acad Dermatol. 2019;80(5):1344\u201352.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"809_CR20","doi-asserted-by":"publisher","first-page":"adv00006","DOI":"10.2340\/00015555-3353","volume":"100","author":"L Guenther","year":"2020","unstructured":"Guenther L, Potts Bleakman A, Weisman J, Poulin Y, Spelman L, Burge R, et al. Ixekizumab results in persistent clinical improvement in moderate-to-severe genital psoriasis during a 52 week, randomized, placebo-controlled, phase 3 clinical trial. Acta Derm Venereol. 2020;100(1):adv00006.","journal-title":"Acta Derm Venereol"},{"issue":"6","key":"809_CR21","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1111\/bjd.18484","volume":"182","author":"AB Kimball","year":"2020","unstructured":"Kimball AB, Papp KA, Reich K, Gooderham M, Li Q, Cichanowitz N, et al. Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studies. Br J Dermatol. 2020;182(6):1359\u201368.","journal-title":"Br J Dermatol"},{"issue":"11","key":"809_CR22","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1111\/1346-8138.17446","volume":"51","author":"SW Youn","year":"2024","unstructured":"Youn SW, Jo SJ, Park CJ, Kim DH, Shin BS, Jeong KH, et al. Bimekizumab efficacy and safety in Korean patients with moderate to severe plaque psoriasis: a phase 3, randomized, placebo-controlled, double-blinded study. J Dermatol. 2024;51(11):1392\u2013403.","journal-title":"J Dermatol"},{"issue":"4","key":"809_CR23","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1111\/bjd.16736","volume":"179","author":"C Ryan","year":"2018","unstructured":"Ryan C, Menter A, Guenther L, Blauvelt A, Bissonnette R, Meeuwis K, et al. Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis. Br J Dermatol. 2018;179(4):844\u201352.","journal-title":"Br J Dermatol"},{"issue":"4","key":"809_CR24","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1111\/bjd.19314","volume":"184","author":"A Blauvelt","year":"2021","unstructured":"Blauvelt A, Paul C, van de Kerkhof P, Warren RB, Gottlieb AB, Langley RG, et al. Long-term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo-controlled studies. Br J Dermatol. 2021;184(4):640\u201351.","journal-title":"Br J Dermatol"},{"issue":"3","key":"809_CR25","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1111\/bjd.20818","volume":"186","author":"KB Gordon","year":"2022","unstructured":"Gordon KB, Lebwohl M, Papp KA, Bachelez H, Wu JJ, Langley RG, et al. Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2022;186(3):466\u201375.","journal-title":"Br J Dermatol"},{"issue":"10","key":"809_CR26","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1111\/1346-8138.13900","volume":"44","author":"NL Wu","year":"2017","unstructured":"Wu NL, Hsu CJ, Sun FJ, Tsai TF. Efficacy and safety of secukinumab in Taiwanese patients with moderate to severe plaque psoriasis: subanalysis from ERASURE phase III study. J Dermatol. 2017;44(10):1129\u201337.","journal-title":"J Dermatol"},{"issue":"2","key":"809_CR27","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s40266-018-0520-z","volume":"35","author":"A Korber","year":"2018","unstructured":"Korber A, Papavassilis C, Bhosekar V, Reinhardt M. Efficacy and safety of secukinumab in elderly subjects with moderate to severe plaque psoriasis: a pooled analysis of phase iii studies. Drugs Aging. 2018;35(2):135\u201344.","journal-title":"Drugs Aging"},{"issue":"3","key":"809_CR28","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.jaad.2023.04.063","volume":"89","author":"B Strober","year":"2023","unstructured":"Strober B, Paul C, Blauvelt A, Thaci D, Puig L, Lebwohl M, et al. Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial. J Am Acad Dermatol. 2023;89(3):486\u201395.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"809_CR29","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1111\/1346-8138.17685","volume":"52","author":"A Morita","year":"2025","unstructured":"Morita A, Imafuku S, Tada Y, Okubo Y, Habiro K, Tsuritani K, et al. Deucravacitinib in plaque psoriasis: safety and efficacy through 3 years in Japanese patients in the phase 3 POETYK PSO-1, PSO-4, and LTE trials. J Dermatol. 2025;52(5):761\u201372.","journal-title":"J Dermatol"},{"key":"809_CR30","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003855","author":"LC Coates","year":"2024","unstructured":"Coates LC, Landew\u00e9 R, McInnes IB, Mease PJ, Ritchlin CT, Tanaka Y, et al. Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL. RMD Open. 2024. https:\/\/doi.org\/10.1136\/rmdopen-2023-003855.","journal-title":"RMD Open"},{"issue":"11","key":"809_CR31","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1002\/acr2.11727","volume":"6","author":"IB McInnes","year":"2024","unstructured":"McInnes IB, Mease PJ, Tanaka Y, Gossec L, Husni ME, Kristensen LE, et al. Efficacy and safety of bimekizumab in patients with psoriatic arthritis with or without methotrexate: 52-week results from two phase 3 studies. ACR Open Rheumatol. 2024;6(11):720\u201331.","journal-title":"ACR Open Rheumatol"},{"issue":"10","key":"809_CR32","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1084\/jem.20061308","volume":"203","author":"SC Liang","year":"2006","unstructured":"Liang SC, Tan XY, Luxenberg DP, Karim R, Dunussi-Joannopoulos K, Collins M, et al. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med. 2006;203(10):2271\u20139.","journal-title":"J Exp Med"},{"issue":"9","key":"809_CR33","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/nri.2017.50","volume":"17","author":"B Stockinger","year":"2017","unstructured":"Stockinger B, Omenetti S. The dichotomous nature of T helper 17 cells. Nat Rev Immunol. 2017;17(9):535\u201344.","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"809_CR34","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.abd.2024.06.001","volume":"99","author":"PR Criado","year":"2024","unstructured":"Criado PR, Miot HA, Bueno-Filho R, Ianhez M, Criado RFJ, de Castro CCS. Update on the pathogenesis of atopic dermatitis. An Bras Dermatol. 2024;99(6):895\u2013915.","journal-title":"An Bras Dermatol"},{"issue":"2","key":"809_CR35","doi-asserted-by":"publisher","first-page":"707","DOI":"10.4049\/jimmunol.1602185","volume":"199","author":"A Floudas","year":"1950","unstructured":"Floudas A, Saunders SP, Moran T, Schwartz C, Hams E, Fitzgerald DC, et al. IL-17 receptor A maintains and protects the skin barrier to prevent allergic skin inflammation. J Immunol. 1950;199(2):707\u201317.","journal-title":"J Immunol"},{"issue":"4","key":"809_CR36","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1111\/jdv.16126","volume":"34","author":"F Lauffer","year":"2020","unstructured":"Lauffer F, Jargosch M, Baghin V, Krause L, Kempf W, Absmaier-Kijak M, et al. IL-17C amplifies epithelial inflammation in human psoriasis and atopic eczema. J Eur Acad Dermatol Venereol JEADV. 2020;34(4):800\u20139.","journal-title":"J Eur Acad Dermatol Venereol JEADV."},{"issue":"11","key":"809_CR37","doi-asserted-by":"publisher","first-page":"5451","DOI":"10.1007\/s12325-025-03363-9","volume":"42","author":"G Han","year":"2025","unstructured":"Han G, Armstrong A, Krueger JG, Jacobson A. IL-17C as a driver of inflammation in psoriasis. Adv Ther. 2025;42(11):5451\u201367.","journal-title":"Adv Ther"},{"issue":"77","key":"809_CR38","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abq3254","volume":"7","author":"SK Whitley","year":"2022","unstructured":"Whitley SK, Li M, Kashem SW, Hirai T, Igy\u00e1rt\u00f3 BZ, Knizner K, et al. Local IL-23 is required for proliferation and retention of skin-resident memory TH17 cells. Sci Immunol. 2022;7(77):eabq3254.","journal-title":"Sci Immunol"},{"key":"809_CR39","doi-asserted-by":"publisher","first-page":"1331217","DOI":"10.3389\/fimmu.2024.1331217","volume":"15","author":"JG Krueger","year":"2024","unstructured":"Krueger JG, Eyerich K, Kuchroo VK, Ritchlin CT, Abreu MT, Elloso MM, et al. IL-23 past, present, and future: a roadmap to advancing IL-23 science and therapy. Front Immunol. 2024;15:1331217.","journal-title":"Front Immunol"},{"issue":"4","key":"809_CR40","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1038\/ng1767","volume":"38","author":"CN Palmer","year":"2006","unstructured":"Palmer CN, Irvine AD, Terron-Kwiatkowski A, Zhao Y, Liao H, Lee SP, et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet. 2006;38(4):441\u20136.","journal-title":"Nat Genet"},{"issue":"2","key":"809_CR41","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.jaci.2006.12.646","volume":"119","author":"T Nomura","year":"2007","unstructured":"Nomura T, Sandilands A, Akiyama M, Liao H, Evans AT, Sakai K, et al. Unique mutations in the filaggrin gene in Japanese patients with ichthyosis vulgaris and atopic dermatitis. J Allergy Clin Immunol. 2007;119(2):434\u201340.","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"809_CR42","doi-asserted-by":"publisher","first-page":"172","DOI":"10.36849\/JDD.6408","volume":"21","author":"R Chovatiya","year":"2022","unstructured":"Chovatiya R, Silverberg JI. The heterogeneity of atopic dermatitis. J Drugs Dermatol. 2022;21(2):172\u20136.","journal-title":"J Drugs Dermatol"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-026-00809-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-026-00809-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-026-00809-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T11:08:42Z","timestamp":1792148922000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-026-00809-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,16]]},"references-count":42,"alternative-id":["809"],"URL":"https:\/\/doi.org\/10.1007\/s40259-026-00809-6","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,16]]},"assertion":[{"value":"30 August 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All data analyzed in this study are derived from published literature, which are cited in the reference list. The extracted data used for the meta-analysis are available from the corresponding author upon reasonable request.","order":2,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This systematic review and meta-analysis used only publicly available aggregate data from previously published studies and did not involve direct human participants, human material, or human data.","order":3,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The statistical analyses were performed using standard packages in R (version 4.3.2), primarily the meta package. No custom code was developed. The R scripts used for the analyses are available from the corresponding author upon reasonable request.","order":6,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Yifei Feng: Conceptualization, Methodology, Data curation, Formal analysis, Writing\u2014original draft. Yan Lu: Conceptualization, Supervision, Writing\u2014review & editing, Funding acquisition. Both authors read and approved the final manuscript.","order":7,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}